This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- 177Lu-3BP-227 for Neurotensin Receptor 1-Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical Results
- Brief Intraperitoneal Radioimmunotherapy of Small Peritoneal Carcinomatosis Using High Activities of Noninternalizing 125I-Labeled Monoclonal Antibodies
- Intraperitoneal {alpha}-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab')2--A Phase I Study
- Targeted Actinium-225 in Vivo Generators for Therapy of Ovarian Cancer
- A Novel Approach for the Increased Delivery of Pharmaceutical Agents to Peritoneum and Associated Lymph Nodes
- Improved Prediction of Myelotoxicity Using a Patient-Specific Imaging Dose Estimate for Non-Marrow-Targeting 90Y-Antibody Therapy
- A Phase I Study of Combined Modality 90Yttrium-CC49 Intraperitoneal Radioimmunotherapy for Ovarian Cancer
- Targeted Therapy of Cancer with Radiolabeled Antibodies
- Radioimmunotherapy of a Human Lung Cancer Xenograft with Monoclonal Antibody RS7: Evaluation of 177Lu and Comparison of Its Efficacy with That of 90Y and Residualizing 131I
- Selectivity of TAG-72-targeted Adenovirus Gene Transfer to Primary Ovarian Carcinoma Cells versus Autologous Mesothelial Cells in Vitro
- Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only
- Phase I Study of 90Y-labeled B72.3 Intraperitoneal Administration in Patients with Ovarian Cancer: Effect of Dose and EDTA Coadministration on Pharmacokinetics and Toxicity
- In Vivo Localization of [111In]-DTPA-D-Phe -Octreotide to Human Ovarian Tumor Xenografts Induced to Express the Somatostatin Receptor Subtype 2 Using an Adenoviral Vector